EGFR and neoplasm: Overall, there were no marked differences in the median percentage of viable tumor in resected tumors with EGFR/ALK alterations between the treatment arms (Extended Data Fig. 3d), whereas deeper median pathological regression was noted in resected tumors harboring KRAS and TP53 alterations between the treatment arms (Extended Data Fig. 3e,f).